FDA Commissioner Marty Makary announced a pilot program to pay bonuses to reviewers who complete drug evaluations ahead of schedule, with the first quarterly payments slated for August. Agency slides and an internal presentation obtained by the Associated Press outlined metrics that will weigh “weighted time savings,” team performance, and work quality. Officials framed the plan as a retention and efficiency move amid staff attrition. Critics warn the program creates perceived incentives to prioritize speed over rigor; FDA leadership states the program “values speed, but never at the expense of quality.” The pilot’s distribution mechanics and safeguards for review integrity remain to be detailed.